Boehringer Ingelheim to advance survodutide into three global phase III studies in obesity

Boehringer Ingelheim announced it will advance survodutide, its glucagon/GLP-1 receptor dual agonist, into three registrational phase III studies for people living with overweight or obesity. This decision was based on recently presented data from a phase II dose finding study in people living with overweight or obesity. The study demonstrated up to 19 per cent weight loss after 46 weeks of treatment with survodutide.

“With a strong heritage in cardio-renal-metabolic disease, we are continuing to expand and accelerate our portfolio in this area with the aim of bringing survodutide to patients in need as quickly as possible,” said Carinne Brouillon, Head of Human Pharma, Boehringer Ingelheim. “There is a significant unmet medical need for effective treatments for obesity. With its dual mode of action, survodutide has the potential to further improve outcomes for people living with the disease and its associated complications.”

Insights from previous studies will now be applied to the design of three global phase III studies, which will investigate the efficacy and safety of survodutide. Details of the studies will be disclosed prior to their initiation and enrollment of patients is planned before the end of 2023.

In 2016, more than 1.9 billion adults were overweight - defined as a body mass index (BMI) of 25 or more, of which over 650 million were living with obesity - defined as a BMI of 30 or more. The World Obesity Federation predicts that by 2025, 2.7 billion adults could be living with overweight or obesity, making it a global health challenge and placing a high burden on individuals, healthcare systems, and society. Overweight and obesity are complex chronic conditions involving abnormal or excessive fat accumulation that presents a risk to a person’s overall health.

Survodutide is a glucagon/GLP-1 receptor dual agonist that activates both the GLP-1 and glucagon receptors, which are critical to controlling metabolic functions. It is also evaluated in a phase II study in adults with NASH and liver fibrosis (stages F1/F2/F3) with and without type 2 diabetes6 for which it received US FDA Fast Track Designation. Co-invented by Boehringer Ingelheim and Zealand Pharma, survodutide is part of Boehringer Ingelheim’s research and development portfolio in the cardio-renal-metabolic disease areas.

Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!